Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI trained to tell dangerous lung nodules from harmless ones

NCT ID NCT07815483

Diagnosis Sponsor: Shanghai East Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 11, 2026 · Last updated Sep 11, 2026

Summary

Researchers are testing artificial intelligence models that analyze CT scans to find lung nodules and estimate whether they are benign or malignant. The study enrolls adults who have at least one non-calcified lung nodule measuring 3 to 30 mm. Participants receive no drugs or procedures; the team collects CT images and medical records from multiple hospitals to see how well the AI classifies nodules and sorts them into risk groups compared with doctors' judgment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
artificial intelligence software for analyzing lung nodule CT scans
What this could lead to
If the AI models perform well, they could help doctors spot dangerous lung nodules earlier and decide which ones need closer follow-up or biopsy.
What could go wrong
The study only observes how the AI performs on existing scans; it does not prove that using the AI improves patient outcomes. The models may not work as well across different hospitals or scanner types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 16,880 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Oct 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Consecutively enrolled, representative patients (aged ≥18 years, with a maximum nodule diameter of ≥3 mm and ≤30 mm) who underwent chest CT for routine clinical care and were found to have pulmonary nodules, including solid, part-solid, and pure ground-glass nodules.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: (1) Age ≥18 years; (2) At least one non-calcified pulmonary nodule (diameter ≥3 mm and ≤30 mm) detected on chest CT; (3) Agreement to participate in the study and provision of written informed consent. \- Exclusion Criteria: 1. Poor CT image quality with severe artifacts that preclude AI-based analysis; 2. Expected survival \<12 months or inability to complete follow-up; 3. History of prior ipsilateral lung malignancy or local treatment. -

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Artificial intelligence (AI) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung neoplasm Multiple Pulmonary Nodules

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Artificial intelligence (AI) Lung neoplasms Pulmonary nodules

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.